Results 11 to 20 of about 1,218 (152)

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI [PDF]

Journal of Diabetes Investigation
Aims/Introduction Patients with type 2 diabetes are at high risk of developing steatotic liver disease (SLD). Weight loss has proven effective in treating metabolic dysfunction‐associated steatotic liver disease (MASLD) in obese patients with type 2 ...
Hiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, Hideki Suganami, Kazunori Utsunomiya, Kohei Kaku, Kyoichiro Tsuchiya   +6 more
doaj   +4 more sources

Tofogliflozin ameliorates cardiotoxin induced skeletal muscle injury and fibrosis in obesity [PDF]

Scientific Reports
Obesity impairs muscle function through effects on lipid metabolism, systemic inflammation, and insulin resistance, leading to muscle loss and reduced regeneration.
Muhammad Bilal, Nguyen Quynh Phuong, Tomonobu Kado, Jianhui Liu, Le Duc Anh, Sana Khalid, Muhammad Rahil Aslam, Memoona, Ayumi Nishimura, Yoshiko Igarashi, Yoshiyuki Watanabe, Waseem Abbas, Maki Yokoyama, Yasuhiro Onogi, Kenichi Hirabayashi, Seiji Yamamoto, Kunimasa Yagi, Marsel Lino, Isao Usui, Masaru Kato, Shiho Fujisaka, Allah Nawaz, Kazuyuki Tobe   +22 more
doaj   +4 more sources

Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice [PDF]

BMC Gastroenterology
Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes ...
Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama, Souichiro Ogawa, Keisuke Uchida, Hotaka Tamura, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata   +11 more
doaj   +4 more sources

The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease [PDF]

Gastroenterology Insights, 2022
The increasing number of patients with fatty liver disease is a major health problem. Fatty liver disease with metabolic dysfunction has been recognized as nonalcoholic fatty liver disease (NAFLD).
Takeshi Goya, Koji Imoto, Shigeki Tashiro, Tomomi Aoyagi, Motoi Takahashi, Miho Kurokawa, Hideo Suzuki, Masatake Tanaka, Masaki Kato, Motoyuki Kohjima, Yoshihiro Ogawa   +10 more
doaj   +2 more sources

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial

Hepatology Communications, 2022
The incidence of nonalcoholic fatty liver disease (NAFLD) has recently increased and is related to obesity and the associated surge in type 2 diabetes mellitus (T2DM) and metabolic syndromes.
Masato Yoneda, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, Masataka Taguri, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima   +10 more
doaj   +3 more sources

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial [PDF]

Cardiovascular Diabetology, 2022
Background Since sodium-glucose cotransporter 2 (SGLT2) inhibitors have a pleiotropic antiatherogenic effect, they are expected to attenuate the progression of atherosclerosis.
Naoto Katakami, Tomoya Mita, Norikazu Maeda, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, The UTOPIA Study Investigators   +6 more
doaj   +3 more sources

Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice [PDF]

Journal of Diabetes Investigation
Aims/Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety.
Yuichiro Yamada, Daisuke Yabe, Kenichiro Shide, Atsushi Suzuki, Yasuo Terauchi, Yasunori Sato, Nobuyuki Shihara, Yutaka Seino   +7 more
doaj   +2 more sources

A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database [PDF]

Scientific Reports
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of drugs used in the clinical management of patients with type 2 diabetes, and their prescriptions have been increasing in recent years.
Kiyoka Matsumoto, Fumiya Goto, Mika Maezawa, Satoshi Nakao, Koumi Miyasaka, Sakiko Hirofuji, Kohei Shiota, Nanaka Ichihara, Moe Yamashita, Yuka Nokura, Tomofumi Yamazaki, Kana Sugishita, Hideyuki Tanaka, Hirofumi Tamaki, Motoyuki Ishiguro, Kazuhiro Iguchi, Mitsuhiro Nakamura   +16 more
doaj   +2 more sources

Effect of sodium-glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims-based cohort study. [PDF]

J Diabetes Investig
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Hiura K, Masuda H, Sakunami M, Yamashita M.   +3 more
europepmc   +2 more sources

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion [PDF]

Scientific Reports
This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin ...
Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka   +5 more
doaj   +2 more sources